Free Trial

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Akari Therapeutics, Plc stock logo
AKTX
Akari Therapeutics
$1.81
-7.2%
$1.51
$1.08
$5.50
$14.34M0.9915,520 shs3,714 shs
Elevai Labs, Inc. stock logo
ELAB
Elevai Labs
$0.64
-4.5%
$0.66
$0.57
$4.24
$12.09MN/A1.01 million shs249,925 shs
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
$4.58
-7.1%
$5.02
$4.28
$15.75
$10.59M1.8528,964 shs32,447 shs
NantHealth, Inc. stock logo
NH
NantHealth
$0.90
+5.9%
$0.74
$1.24
$9.75
$6.93M1.8238,073 shs16,014 shs
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Akari Therapeutics, Plc stock logo
AKTX
Akari Therapeutics
0.00%+25.81%+64.56%-15.22%-47.33%
Elevai Labs, Inc. stock logo
ELAB
Elevai Labs
0.00%-1.02%+1.36%-3.19%+66,809,900.00%
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
0.00%-0.40%+6.48%-46.65%-43.23%
NantHealth, Inc. stock logo
NH
NantHealth
0.00%-22.61%+43.74%+198.68%-36.94%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Akari Therapeutics, Plc stock logo
AKTX
Akari Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Elevai Labs, Inc. stock logo
ELAB
Elevai Labs
N/AN/AN/AN/AN/AN/AN/AN/A
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
2.2333 of 5 stars
3.53.00.00.02.90.01.3
NantHealth, Inc. stock logo
NH
NantHealth
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Akari Therapeutics, Plc stock logo
AKTX
Akari Therapeutics
N/AN/AN/AN/A
Elevai Labs, Inc. stock logo
ELAB
Elevai Labs
N/AN/AN/AN/A
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
3.00
Buy$35.00664.19% Upside
NantHealth, Inc. stock logo
NH
NantHealth
N/AN/AN/AN/A

Current Analyst Ratings

Latest NH, ELAB, AKTX, and MBRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/12/2024
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
Roth Mkm
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$40.00
3/26/2024
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$45.00 ➝ $20.00
(Data available from 5/28/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Akari Therapeutics, Plc stock logo
AKTX
Akari Therapeutics
N/AN/AN/AN/A($0.03) per shareN/A
Elevai Labs, Inc. stock logo
ELAB
Elevai Labs
$1.71M7.07N/AN/A$0.22 per share2.91
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
N/AN/AN/AN/A$11.70 per shareN/A
NantHealth, Inc. stock logo
NH
NantHealth
$67.68M0.10N/AN/A($30.72) per share-0.03

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Akari Therapeutics, Plc stock logo
AKTX
Akari Therapeutics
-$10.01MN/A0.00N/AN/AN/AN/AN/A
Elevai Labs, Inc. stock logo
ELAB
Elevai Labs
-$4.30M-$0.37N/AN/A-211.25%-225.32%-125.94%9/26/2024 (Estimated)
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
-$29.77MN/A0.00N/AN/AN/A-87.19%-68.91%8/9/2024 (Estimated)
NantHealth, Inc. stock logo
NH
NantHealth
-$67.78M-$7.65N/AN/A-94.67%N/A-39.82%N/A

Latest NH, ELAB, AKTX, and MBRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2024Q1 2024
Elevai Labs, Inc. stock logo
ELAB
Elevai Labs
N/A-$0.08-$0.08-$0.08N/A$0.62 million
3/29/2024Q4 2023
Elevai Labs, Inc. stock logo
ELAB
Elevai Labs
N/A-$0.08-$0.08-$0.08N/A$0.70 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Akari Therapeutics, Plc stock logo
AKTX
Akari Therapeutics
N/AN/AN/AN/AN/A
Elevai Labs, Inc. stock logo
ELAB
Elevai Labs
N/AN/AN/AN/AN/A
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
N/AN/AN/AN/AN/A
NantHealth, Inc. stock logo
NH
NantHealth
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Akari Therapeutics, Plc stock logo
AKTX
Akari Therapeutics
N/A
0.44
0.44
Elevai Labs, Inc. stock logo
ELAB
Elevai Labs
0.20
2.57
1.80
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
N/A
3.51
3.51
NantHealth, Inc. stock logo
NH
NantHealth
N/A
0.64
0.64

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Akari Therapeutics, Plc stock logo
AKTX
Akari Therapeutics
5.06%
Elevai Labs, Inc. stock logo
ELAB
Elevai Labs
22.22%
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
15.52%
NantHealth, Inc. stock logo
NH
NantHealth
4.50%

Insider Ownership

CompanyInsider Ownership
Akari Therapeutics, Plc stock logo
AKTX
Akari Therapeutics
61.80%
Elevai Labs, Inc. stock logo
ELAB
Elevai Labs
N/A
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
6.70%
NantHealth, Inc. stock logo
NH
NantHealth
61.30%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Akari Therapeutics, Plc stock logo
AKTX
Akari Therapeutics
97.92 million3.03 millionNot Optionable
Elevai Labs, Inc. stock logo
ELAB
Elevai Labs
1818.89 millionN/AN/A
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
182.31 million2.16 millionNot Optionable
NantHealth, Inc. stock logo
NH
NantHealth
3267.70 million2.98 millionNot Optionable

NH, ELAB, AKTX, and MBRX Headlines

Recent News About These Companies

StockNews.com Begins Coverage on NantHealth (NASDAQ:NH)
NantHealth welcomes chief legal officer
WorkWISE NH
13 Most Romantic Getaways in New Hampshire
Therapists in Rochester, NH

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Akari Therapeutics logo

Akari Therapeutics

NASDAQ:AKTX
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.
Elevai Labs logo

Elevai Labs

NASDAQ:ELAB
Elevai Labs, Inc., a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc. and changed its name to Elevai Labs, Inc. in December 2021. Elevai Labs, Inc. was incorporated in 2020 and is based in Newport Beach, California.
Moleculin Biotech logo

Moleculin Biotech

NASDAQ:MBRX
Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.
NantHealth logo

NantHealth

NASDAQ:NH
NantHealth, Inc. engages in the provision of enterprise solutions that help businesses transform complex data into actionable insights. It is also involved in marketing solutions as a comprehensive integrated solution that includes clinical decision support, payer engagement solutions, data analysis, and network monitoring and management. The company was founded by Patrick Soon-Shiong on July 7, 2010 and is headquartered in Morrisville, NC.